81 Result(s)
within
Christie M. Ballantyne
-
Article
Oral PCSK9 Inhibitors
In this review, we will discuss the data from early clinical studies of MK-0616 and summarize clinical trials of other oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.
-
Article
Open AccessClonal hematopoiesis of indeterminate potential is associated with acute kidney injury
Age is a predominant risk factor for acute kidney injury (AKI), yet the biological mechanisms underlying this risk are largely unknown. Clonal hematopoiesis of indeterminate potential (CHIP) confers increased ...
-
Article
Open AccessRNA interference targeting ANGPTL3 for triglyceride and cholesterol lowering: phase 1 basket trial cohorts
Elevated triglycerides and non-high-density lipoprotein cholesterol (HDL-C) are risk factors for atherosclerotic cardiovascular disease (ASCVD). ARO-ANG3 is an RNA interference therapy that targets angiopoieti...
-
Article
Open AccessCorrection to: Plasma proteins related to inflammatory diet predict future cognitive impairment
-
Article
Open AccessPlasma proteins related to inflammatory diet predict future cognitive impairment
Dysregulation of the immune system and dietary patterns that increase inflammation can increase the risk for cognitive decline, but the mechanisms by which inflammatory nutritional habits may affect the develo...
-
Article
Open AccessEvinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial
Severe hypertriglyceridemia (sHTG) is an established risk factor for acute pancreatitis. Current therapeutic approaches for sHTG are often insufficient to reduce triglycerides and prevent acute pancreatitis. T...
-
Article
TP53-mediated clonal hematopoiesis confers increased risk for incident atherosclerotic disease
Somatic mutations in blood indicative of clonal hematopoiesis of indeterminate potential (CHIP) are associated with an increased risk of hematologic malignancy, coronary artery disease and all-cause mortality....
-
Article
Open AccessClonal hematopoiesis of indeterminate potential, DNA methylation, and risk for coronary artery disease
Age-related changes to the genome-wide DNA methylation (DNAm) pattern observed in blood are well-documented. Clonal hematopoiesis of indeterminate potential (CHIP), characterized by the age-related acquisition...
-
Article
Open AccessAuthor Correction: Increased prevalence of clonal hematopoiesis of indeterminate potential amongst people living with HIV
-
Article
Diabetes, GDF-15 and incident heart failure: the atherosclerosis risk in communities study
Elevated circulating growth differentiation factor-15 (GDF-15), a marker of cellular stress, is associated with both heart failure (HF) and diabetes. However, it is unclear to what extent GDF-15 is associated ...
-
Article
Facility-Level Variation in Reported Statin-Associated Side Effects Among Patients with Atherosclerotic Cardiovascular Disease—Perspective from the Veterans Affair Healthcare System
Statin-associated side effects (SASEs) can limit statin adherence and present a potential barrier to optimal statin utilization. How standardized reporting of SASEs varies across medical facilities has not bee...
-
Article
Significant Facility-Level Variation in Utilization of and Adherence with Secondary Prevention Therapies Among Patients with Premature Atherosclerotic Cardiovascular Disease: Insights from the VITAL (Veterans wIth premaTure AtheroscLerosis) Registry7
We investigated facility-level variation in the use and adherence with antiplatelets and statins among patients with premature and extremely premature ASCVD.
-
Article
Open AccessIncreased prevalence of clonal hematopoiesis of indeterminate potential amongst people living with HIV
People living with human immunodeficiency virus (PLWH) have significantly increased risk for cardiovascular disease in part due to inflammation and immune dysregulation. Clonal hematopoiesis of indeterminate p...
-
Chapter
Hypercholesterolemia
Hypercholesterolemia, and elevation of low-density lipoprotein cholesterol (LDL-C) in particular, is a known risk factor for the development and progression of atherosclerotic cardiovascular disease (ASCVD). P...
-
Article
PCSK9-targeted therapies: present and future approaches
Human genetic studies combined with biotechnological advances have guided and accelerated the development of PCSK9-targeting therapies. In this Clinical Outlook, we highlight present and future approaches for ...
-
Article
Lipid-Lowering Biotechnological Drugs: from Monoclonal Antibodies to Antisense Therapies—a Clinical Perspective
While low density lipoprotein cholesterol (LDL-C) remains a key contributor of atherosclerotic cardiovascular disease (ASCVD), additional risk factors identified through epidemiological and genetic studies hav...
-
Article
Open AccessEndothelium-specific depletion of LRP1 improves glucose homeostasis through inducing osteocalcin
The vascular endothelium is present within metabolic organs and actively regulates energy metabolism. Here we show osteocalcin, recognized as a bone-secreted metabolic hormone, is expressed in mouse primary en...
-
Article
Open AccessCorrection to: Role of Bempedoic Acid in Clinical Practice
A Correction to this paper has been published: https://doi.org/10.1007/s10557-021-07188-w
-
Article
Association Between Omega-3 Fatty Acid Treatment and Atrial Fibrillation in Cardiovascular Outcome Trials: A Systematic Review and Meta-Analysis
Data on the relationship between omega-3 fatty acid (n-3 FA) therapy with atrial fibrillation (AF) have been inconsistent. We investigate the association between n-3 FA and risk for AF by pooling data from ava...
-
Article
Open AccessRole of Bempedoic Acid in Clinical Practice
Many patients do not achieve optimal low-density lipoprotein cholesterol (LDL-C) levels with statins alone; others are unable to tolerate statin therapy. Additional non-statin treatment options including ezeti...
